Index/Organizations/Kidney Disease: Improving Global Outcomes

Kidney Disease: Improving Global Outcomes

International nonprofit organization

Fact-Checks

4 results

Jan 18, 2026

What do guidelines recommend for choosing GLP‑1 RA vs SGLT‑2 inhibitor in patients with type 2 diabetes and eGFR <45 mL/min/1.73 m2?

Guidelines converge on a risk‑based, not purely glycemia‑based, choice: SGLT2 inhibitors are recommended for cardiorenal protection down to low eGFR thresholds (often ≥20 mL/min/1.73 m2) despite reduc...

Jan 5, 2026

What are recommended monitoring strategies for renal function when administering antiparasitic drugs in patients with CKD or polypharmacy?

Patients with chronic kidney disease (CKD) or heavy polypharmacy require systematic renal monitoring when prescribed antiparasitic agents because impaired renal clearance and drug–drug interactions ch...

Dec 16, 2025

Which groups need routine iron screening and how is deficiency diagnosed?

Routine screening is recommended for high‑risk groups: pregnant people (guideline debate exists over universal vs targeted screening) and women of reproductive age/heavy menstrual bleeding; children a...

Nov 19, 2025

How do comorbidities (diabetes, CKD, familial hypercholesterolemia) change statin initiation recommendations in 2025?

Major 2024–2025 guidelines and reviews treat diabetes, chronic kidney disease (CKD), and familial hypercholesterolemia (FH) as “statin‑indicated” or risk‑enhancing conditions that lower the threshold ...